Video

Dr. Eyre on the Design of the BRUIN-MCL-321 Trial in MCL

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, discusses the design and the rationale of the phase 3 BRUIN-MCL-321 trial in mantle cell lymphoma.

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, consultant hematologist, Oxford University Hospitals, discusses the design and the rationale of the phase 3 BRUIN-MCL-321 trial (NCT04662255) in mantle cell lymphoma (MCL).

BRUIN-MCL-321 is evaluating the noncovalent BTK inhibitor pirtobrutinib (LOXO-305) vs approved BTK inhibitors, including ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa), in previously treated patients with MCL.

Treatment in the control arm will be investigator’s choice of ibrutinib, acalabrutinib, or zanubrutinib, based on what is available in various locations, Eyre explains. Althoughpatients are required to have undergone prior treatment for MCL, they must be BTK inhibitor naïve, Eyre notes.

Once enrolled, patients will be randomized 1:1 to receive oral pirtobrutinib at 200 mg once daily, or standard of care. The trial expects to enroll approximately 500 patients, Eyre concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity